BioAtla, Inc.
—
Loading prices…
Daily prices
Rank vs the other stocks
Trading model · trial run, not placing orders yet
54thpercentile
WeakestStrongest
BCAB placed in the 54th percentile of the stocks being followed just after the open on . The trading model buys from the top of this list.
- Model score
- +0.09
- Ranked
Old model
Guesses whether the price goes up or down. Latest call: Hold
Next day
↓ Down
1% confidence
Next 2 days
↓ Down
9% confidence
Made
Technical signals
Momentum, trend, volatility and volume from recent trading, as of
Momentum
- RSI (14)
- 0.560
- Stochastic %K (14)
- 0.907
- Stochastic %D (14)
- 0.416
Trend
- Price vs SMA (20)
- 0.244
- Price vs EMA (26)
- 0.137
- Price vs WMA (20)
- 0.243
Volatility
- Bollinger %B (20/2)
- 1.167
- Bollinger Bandwidth (20/2)
- 0.366
- ATR % (14)
- 0.160
Volume
- OBV change (20)
- 0.147
- Money Flow Index (14)
- 0.642
- Chaikin Money Flow (20)
- −0.070
Returns & Statistics
- Return (1)
- 0.330
- Return (2)
- 0.232
- Overnight gap
- 0.138
Latest signals
Loading signals…
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated…
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- OQB
- Currency
- USD
News
No recent news about BCAB.
Locations
Where the company has offices, plants and other sites. Used to judge supply-chain and regional risk.